Piper Sandler Downgrades Achilles Therapeutics to Neutral, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro downgraded Achilles Therapeutics (ACHL) from Overweight to Neutral and reduced the price target from $8 to $2.

April 05, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Achilles Therapeutics was downgraded by Piper Sandler from Overweight to Neutral, with a significant reduction in price target from $8 to $2.
The downgrade from Overweight to Neutral by a prominent analyst, along with a drastic reduction in the price target, is likely to negatively impact investor sentiment and the stock price of Achilles Therapeutics in the short term. Such analyst actions often lead to immediate market reactions, as they are seen as a significant change in the stock's outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100